Tron Logo
Trade on HitBTC
Like this video

Ratings Embleema

Empowering Patients to Own Their Health Data

Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs. Connecting patients directly to medical research and incentivizing them to share their data with tokens, blockchain is the decentralized technology everyone was waiting for to move away from the current linear process of drug approvals, to a new iterative model where trustworthy digital health data is shared in real time between patients, life sciences and regulators. The 21st Century Cures Act (2016) gave the FDA a mandate to accelerate approvals if more patient real world data was shared proactively by pharma. Embleema's blockchain speeds up this process with patient buy-in, accelerating time to market new drugs.

7 6 expert ratings
Benchy 3.9
Review: coming soon PRO
1 RWE = 0.2 USD
Soft cap
2,000,000 USD
Hard cap
30,000,000 USD
Restricted areas
USA, Canada, China, Iran, Sudan, Syria, North Korea, Crimea, New Zealand, Cuba
Visit ICO website


All ratings published on ICObench serve informational purposes only. ICObench does not provide investment forecast, recommendations or any consulting for that matter. Thus, neither ICObench, nor the experts can be hold responsible for the visitors’ investment decisions. Read more
Clemen Chiang
Ph.D. | CEO | FinTech in Stocks | Blockchain in Cryptos | Author of Amazon Best Sellers in Online Trading
Rated on Nov 14, 2018

A very strong team has been assembled to execute this project.

Idea is similar to Google Health where users input their health records so that they can be shared with relevant medical agencies. However, Google decided to "kill" this project.

As such, the team needs to address the potential of its market size and why blockchain technology can position this project differently.

And here's your competition:

All the best!

Krishnendu Chatterjee Ph.D.
Blockchain | Tokenization Strategist| Whitepaper|Tokenomics | BD| Fundraising
Rated on Nov 16, 2018
Modified on Dec 13, 2018

White paper - The white paper has outlined the problems plaguing the healthcare industry and outlined possible solutions to tackle the problems in a structured manner. The benefits of using blockchain have been well established in healthcare sector (not an original idea!) but the twist is to focus on particular areas to find wider acceptance. The white paper almost has all the details for investors to make an informed decision.

Team - The core team is competent along with a small advisory board. The team is loaded with “visible” experience in the healthcare industry but lacks members capable to fulfill all requirements like blockchain engineers, PR, marketing people etc.

Tokenomics - The token allotment is quite skewed. They have 30% tokens for token sale, 7% tokens for marketing of ICO, 48% tokens (a rather hefty amount) for incentivizing data owners and network growth and 15% tokens for founders. Founders token are vested over a period of 5 years. A huge positive compared to other ICOs. Funds allocation is within reasonable limits and management team takes a further 13% from raised funds so effectively the founders have 15% tokens + 13% from raised funds which is a bit on the higher side but acceptable.

Business Model - The business model requires partnerships and collaborations which has been clearly highlighted including patient advocacy group (Cystic Fibrosis Community), pharmaceuticals (pilot with Pierre Fabre group) etc. A big positive for any project. But they have failed to mention advantages for investors...How do you plan to incentivize investors to hold the coin? Not clear.

MVP/ DApp/ Working Product  - They already have a fully functional working prototype.

The idea is not original but the approach of tackling the problems is! A capable team but only selling 30% as utility tokens for investors makes it a project with long-term benefits. The team should clearly explain benefits for investors which is lacking….

W.r.t to recent discussions and news - Updating the ratings!
"1. Firstly : no competitors, as we know as of today, are able to show a real, live product like we do at Embleema Inc. You can check the code and the contracts on Github. No BS ! We've made the choice to spend our money in our product first, not into communication with a nice whitepaper. Our live product is actually our first marketing asset.

Secondly : as I said earlier, not only we do have a product, but we are able to sell it ! We just signed our first major client : Pierre Fabre Pharma (2.5 billions $ turnover yearly) -->

and we will announce other major clients soon, we're just waiting for the PR to be validated. Several other business proposals are in discussions with governments and other big pharmas VPs & CEOs -->

Third : by acquiring RWD tokens, you actively participate in accelerating research against cancer, rare diseases and other chronic diseases, like Multiple Sclerosis, Crohn's disease and others. Moreover, we are honored to benefit from the support of Patients Associations and government officials, as you can check on our Youtube channel :

We've go a team of healthcare veterans, former Directors of IBM and IMS Health, the world leader in health data."

Stephen Walker
Head of Sales - Asia Pacific - Mapcite Ltd
Rated on Nov 12, 2018

I like the concept here and it looks like the team have the spread of experience required to execute. There may be challenges crossing geographical borders with different laws and standards to address as well as cultural barriers. They seem to have got to a point with the product that shows understanding and a direction. Good project potentially.

Alexis NormandICO team member replied on 12 Nov 2018
Hi Stephen,
Thank you for looking into this. We are laser focused on the US, where our live product is compatible with HIPAA compliant regulations and medical record formats. It is also the biggest life sciences market in the world. This is where we start.

This is our priority because it is perhaps the only country where 90% of people have electronic medical records, thanks to the Meaningful Care act passed in 2008, which subsidized massively the adoption of Electronic Health Records in the US by providers. This means that from a privacy perspective, we must comply with HIPAA regulations, the US norm for protecting electronic personal health information (ePHI), applicable to covered entities (hospitals, payers...) and their business associates (companies performing services on their behalf). In short, anything that can identify you as a patient is considered ephi. It must be stored on a HIPAA compliant server. To make this compatible with a decentralized technology, ePHI such as name & identity must be stored off-chain, with medical data on the blockchain, to allow patient ownership in sharing or in case of compensation.

In France, where we are also beginning to gain traction, regulations that apply are a combination of EU GDPR regulations defining what health data is, and national legislation regarding storage of such data, similar to HIPAA but with slightly different requirements.
Viktor Tabori
Co-founder, CTO
Rated on Mar 20, 2018
This rating's weight is reduced by 50% as there is no review added.
Alexis NormandICO team member replied on 29 Oct 2018
Hi Viktor,
Thanks for rating Embleema in its early stage. Our team has brought in some healthcare industry veterans, released a live product and signed on two pharma companies. I would be happy to discuss with you, to convince you that our project deserves a better ranking.
Yao Min Ng, CBP
| CBP, CBE, CCE |Currently @ Xtheta Singapore, a cryptocurrency exchange | ICO Advisor | IMMO High 1000 | ICOs Investments | Exchanges Listings
Rated on Nov 12, 2018
Modified on Nov 12, 2018

While I agree that such a health care blockchain can be vital to improving the healthcare system.

I have one very fundermental questions, if there exists so many so call health care blockchain can the differnt chains actually share their data seemlessly between one another?

What if different hospitals decided to go onto different chains (assuming mix of both ethereum and other private chains)?

I do however love the vision of Embleema but above issue is something we still need to consider.

Team wise, kyc has pass, not the best of team but still good. May need one or two expert of BC as advisor to add some credibility.

Putting that aside the importance of this is network externalities or how to get it, which means how to get patients to onboard as well as hospitals to participate. In the end it should be the largest chain in the country or area that would win, for example say largest in Paris, then most hospitals in Paris would join the system.

Product wise, mvp and timeline avail so a 4 is rewarded.

Iulian Anghelin
ICO - STO - DAICO Advisor, Investor Relations, Public Speaker
Rated on Feb 28, 2019

Surely one of the most interesting, valuable and well executed projects I have encountered. Every day I look at hundreds of embarrassing projects, to which I don't even give rating gives because I could not find the most suitable words, but here finally I have redone my eyes, some good project is being born.

Finally a project that is launching in the health industry and has within its staff, doctors, researchers and people of the pharmaceutical industry and not only "jackals" in search of easy money, and then see if something advances to develop the project. Even if I could not identify the Blockchain developer or the developer of the platform, the work is done, as there are data and updates on github, while the MVP is already working and offers an exceptional overview of the product they are about to launch. The team regularly participates in various Blockchain events and it's visible.

The social and communication channels are well updated and cared for, but the community is missing, or is very short. Perhaps a bounty campaign, or any other marketing campaign to get attention could be done.

Website and whitepaper executed in an exemplary way, pleasant to look/read, detailed and treated in detail. Tokenomics clear (even if a little more reserve fund I would put), business model equally clear, perhaps the only thing not clear is the big difference between the Softcap (2M) and the Hardcap (30M). The whitepaper contains all the necessary aspects and they did not include text only to make numbers and increase the content, but everything seems studied and well distributed. The presentation video is also excellent.

Many projects are emerging in this area, but certainly this is one of the top, if not the top, until today.

I wish you good luck in fundraising, I hope you can achieve your goals.

ICO analyzer bot

Experts are independently and voluntarily contributing to the community. If no expert has rated the ICO, only ICO analyzer's results are used. Always research before investing as these ratings should not be taken as an investing guide of any kind.

Ratings and ICO analyzer results are being updated (re-calculated) every few hours.

Add to bookmarks
ICO KYC Report
2 members invited
Robert Chu
Prashant Khambekar
KYC procedure verifies selected/specific team members only. It does not guarantee ICO success nor is a call for investment.
Missing or incorrect data? Let us know.

ICOs that might interest you



The NWP solution is a platform that integrates smart devices and databases into a singl...



HighVibe.Network is a blockchain-based ecosystem designed to elevate human consciousnes...



"NurseToken is the solution that hospitals and nurses have desperately needed for years...



Medicohealth Platform will allow for fully anonymous, safe, and efficient communication...

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn more Got it